Partner Headlines - LLY

  1. Biotech Lilly Upgraded On Alzheimer's Drug's $7.5 Billion Potential

    IBD
  2. Biosimilars In Limelight On FDA Approval Of Amgen Drug

    TalkMarkets
  3. Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to ...

    TalkMarkets
  4. Southern Company Leads 52 Stocks Going Ex-Dividend Next Week

    Dividend.com
  5. Biogen Stock Pops As Merck, Allergan Reportedly Probing Buyout

    Investors Business Daily
  6. AbbVie, Merck Beat Earnings Estimates, But Sanofi Lags

    Investors Business Daily
  7. Alder Biopharma Migraine Drug Holds Up After 6 Months

    Investors Business Daily
  8. Lilly, J&J, Novo Battle For Diabetes Market Heats Up; FDA Rulings ...

    Investors Business Daily
  9. Top Funds Heart Edward Lifesciences, Bump Lilly

    IBD
  10. Merck Stock Slides As Q4 Revenue, Guidance Miss Expectations

    IBD
  11. Earnings Recap For January 28

    Benzinga
  12. Eli Lilly Punished For Inline Report

    Benzinga
  13. JNJ Kicks Off Health Care Earnings—What About Deals, Buybacks?

    Benzinga
  14. Stock Marquee Crowded With Oil, Apple, and the Fed

    Benzinga
  15. Last-Hour Rally Erases Midday Losses As Indexes Close Mixed

    IBD
  16. Steven Cohen Makes Eli Lilly, Kraft Heinz Top New Buys

    GuruFocus
  17. A Calmer Year For Pharma?

    IBD
  18. 3 Potential Blockbuster Drugs Launching in 2016

    IBD
  19. Lilly Counts On Pipeline In '16

    IBD
  20. Lilly Guidance Misses Estimates On Lower Sales

    IBD
  21. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD
  22. 5 Top Stocks of the Outperforming Vanguard Health Care Fund

    GuruFocus
  23. Mairs and Power Sells Baxalta, Walt Disney, Target

    GuruFocus
  24. Strategic Beta ETFs Among Year's Top Performers

    IBD
  25. Benzinga's Top Upgrades

    Benzinga
  26. GoPro PT Cut; Chipotle, Bluebird Bio Downgraded

    IBD
  27. Cautious Stock Rebound as Jobs Data Delivers But Wages Still ...

    Benzinga
  28. Lilly Ends Basal Insulin Peglispro Development Program

    Benzinga
  29. HOTCHKIS & WILEY Buys More Than 7 Million Shares in Oil and Gas ...

    GuruFocus
  30. Merck

    IBD
  31. 3 Big Pharma Upgrades (And One Downgrade) At Barclays

    IBD
  32. Amazon's PT Raised; Yum, J&J, Merck, Lilly Upgraded

    IBD
  33. Benzinga's Top Upgrades

    Benzinga
  34. Sanofi Chipping Away At Biogen's MS Dominance

    IBD
  35. Steven Cohen Hikes Stake in Microsoft by More Than 50,000%

    GuruFocus
  36. Biotechs Weaken, But These Names Have Bullish Charts

    IBD
  37. Eli Lilly Release Confirms FDA Approval If Portrazza

    Benzinga
  38. Lilly and Merck Expand Immuno-oncology Collaboration with Phase ...

    Benzinga
  39. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD
  40. PRIMECAP Sells Stake in Technology Company

    GuruFocus
  41. Benzinga's Top Upgrades

    Benzinga
  42. ELI LILLY

    IBD
  43. Lilly, Incyte Announce Data Demonstrate Baricitinib Superiority ...

    Benzinga
  44. DOJ Eyes Lilly, Merck Pricing

    IBD
  45. How This Top Stock Mutual Fund Manager Seeks Growth

    IBD
  46. How This Top Stock Mutual Fund Manager Seeks Growth

    IBD
  47. Sanofi, Novo Nordisk Slide On Diabetes Headwinds

    IBD
  48. Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase ...

    Benzinga
  49. Eli Lilly Q3 Earnings, Guidance Beat On Cost Control

    IBD
  50. Eli Lilly CEO: Our Drug Prices are Fair

    FoxBusiness
  51. McDonald's Strong 3Q Helps Wall Street Jump

    FoxBusiness
  52. Eli Lilly Posts Upbeat Q3 Earnings, Raises Forecast

    Benzinga
  53. Eli Lilly Reports Mixed 3Q Results

    FoxBusiness
  54. Lilly supports global Dementia Discovery Fund

    Benzinga
  55. Wal-Mart's $21 Billion Loss Lost on NYSE Officials

    FoxBusiness
  56. Lilly-Incyte drug beats Humira

    IBD
  57. Lilly-Incyte Drug Beats Humira In Arthritis Trial

    IBD
  58. US Stock Futures Down; JPMorgan Earnings In Focus

    Benzinga
  59. Lilly and ImaginAb Announce Preclinical Immuno-Oncology Collaboration, ...

    Benzinga
  60. Fast Money Traders Share Their Thoughts On Eli Lilly and And ...

    Benzinga
  61. Eli Lilly Pulls Cholesterol Drug

    IBD
  62. Indexes Close Up Across The Board; Facebook Gains, But Twitter ...

    IBD
  63. Stocks Near Flatline; Bad News for Lilly Is Good News For Regeneron

    IBD
  64. Regeneron Stock Pops But Hits Resistance At 50-Day

    IBD
  65. Lilly Kills 'High Risk/High Reward' Cholesterol Drug

    IBD
  66. Stocks Poised For Modestly Higher Start; EMC Jumps In Premarket

    IBD
  67. US Stock Futures Flat Ahead Of Fed Speakers

    Benzinga
  68. Lilly, Innovent Biologics Expand Their Strategic Alliance

    Benzinga
  69. Eli Lilly

    IBD
  70. Lilly Upgraded On Bullish Diabetes Outlook

    IBD
  71. Benzinga's Top Upgrades

    Benzinga
  72. Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib ...

    Benzinga
  73. A Cholesterol Drug Revolution

    IBD
  74. Are Cholesterol Drugs In For Another Revolution?

    IBD
  75. Morning Market Losers

    Benzinga
  76. Despite EU OK, Regeneron Crumbles Below 200-Day

    IBD
  77. Lilly's CYRAMZA® (ramucirumab) Significantly Improves Progression-Free ...

    Benzinga
  78. AbbVie Spurns Galapagos To Advance Own Arthritis Drug

    IBD
  79. Forget The 2016 Election Candidates, CEOs Are Driving Change

    Benzinga
  80. Lilly's New Diabetes Drug Delivers "One of a Kind" Results

    FoxBusiness
  81. Benzinga's Top Initiations

    Benzinga
  82. U.S. District Court Rules in Lilly's Favor on Alimta Vitamin ...

    Benzinga
  83. Benzinga's Volume Movers

    Benzinga
  84. Lilly Issues Update on Evacetrapib Phase 3 Trial: Last Patient ...

    Benzinga
  85. Biogen's Big-Volume Plunge Marks End Of 5-Year Run

    IBD
  86. Valeant Posts Princely Gains

    IBD
  87. 3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates

    IBD
  88. Shire Lifts 2015 Guidance On Strong Drug Pipeline

    IBD
  89. Lilly, Bristol-Myers Beat Q2 Views, Lift Guidance

    IBD
  90. Valeant Earnings Soar On M&A, Organic Sales Growth

    IBD
  91. Wall Street Struggles for Direction After Two-Day Selloff

    FoxBusiness
  92. Alzheimer's Data Diverge

    IBD
  93. Biogen, Lilly Alzheimer's Data Spark Street Debate

    IBD
  94. Are We Any Closer to Finding a Drug to Battle Alzheimer's?

    FoxBusiness
  95. Data Using New Delayed-Start Methodology Suggested Benefit of ...

    Benzinga
  96. Fast Money Picks For July 21

    Benzinga
  97. 6 Big-Cap Drugmakers Reporting Earnings Next Week

    IBD
  98. Celgene Hits High As Street Applauds Receptos Buyout

    IBD
  99. Manning & Napier Advisors' Most Weighted Trades in Q2 2015

    GuruFocus
  100. Weekly 52-Week Highs Highlight: LLY, PLL, SBUX, VLO

    GuruFocus
Trading Center